PEGylation of a Vesicular Stomatitis Virus G Pseudotyped Lentivirus Vector Prevents Inactivation in Serum

ABSTRACT One disadvantage of vesicular stomatitis virus G (VSV-G) pseudotyped lentivirus vectors for clinical application is inactivation of the vector by human serum complement. To prevent this, monomethoxypoly(ethylene) glycol was conjugated to a VSV-G-human immunodeficiency virus vector expressing Escherichia coli beta-galactosidase. The modification did not affect transduction efficiency in vitro and protected the vector from inactivation in complement-active human and mouse sera. Blood from mice dosed intravenously with either the unmodified or the PEGylated virus particles was assayed for active vector by a limiting-dilution assay to evaluate transduction efficiency and for p24, an indicator of the total number of virus particles present. PEGylation extended the circulation half-life of active vector by a factor of 5 and reduced the rate of vector inactivation in the serum by a factor of 1,000. Pharmacokinetic profiles for the total number of virus particles present in the circulation were unaffected by PEGylation. Modification of the vector with poly(ethylene) glycol significantly enhanced transduction efficiency in the bone marrow and in the spleen 14 days after systemic administration of the virus. These results, in concert with the pharmacokinetic profiles, indicate that PEGylation does protect the virus from inactivation in the serum and, as a result, improves the transduction efficiency of VSV-G pseudotyped lentivirus vectors in susceptible organs in vivo.

[1]  M. Ishizaki,et al.  Lentivirus-mediated expression of angiostatin efficiently inhibits neovascularization in a murine proliferative retinopathy model , 2003, Gene Therapy.

[2]  E. Barklis,et al.  Retrovirus capsid protein assembly arrangements. , 2003, Journal of molecular biology.

[3]  James M. Wilson,et al.  PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. , 2002, Human gene therapy.

[4]  E. Bonfils,et al.  A Short-Term Field Use and Shipping Stability Study of a Wild Type Ad5 Adenoviral Reference Material , 2002 .

[5]  I. Martins,et al.  In Vivo Gene Transfer Using a Nonprimate Lentiviral Vector Pseudotyped with Ross River Virus Glycoproteins , 2002, Journal of Virology.

[6]  L. Naldini,et al.  Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. , 2002, Blood.

[7]  I. Verma,et al.  Biodistribution and toxicity studies of VSVG-pseudotyped lentiviral vector after intravenous administration in mice with the observation of in vivo transduction of bone marrow. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[8]  M. Takeuchi,et al.  The eye's view of antigen presentation. , 2002, Human immunology.

[9]  Peter J. Dailey,et al.  The Liver Is a Major Organ for Clearing Simian Immunodeficiency Virus in Rhesus Monkeys , 2002, Journal of Virology.

[10]  G. Kobinger,et al.  Targeted transduction patterns in the mouse brain by lentivirus vectors pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV envelope proteins. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  B. Davidson,et al.  Gene transfer to the nonhuman primate retina with recombinant feline immunodeficiency virus vectors. , 2002, Human gene therapy.

[12]  M. Kay,et al.  Role of hepatocyte direct hyperplasia in lentivirus-mediated liver transduction in vivo. , 2002, Human gene therapy.

[13]  G. Gusella,et al.  Lentiviral gene transduction of kidney. , 2002, Human gene therapy.

[14]  M. Westphal,et al.  Oncoretrovirus and Lentivirus Vectors Pseudotyped with Lymphocytic Choriomeningitis Virus Glycoprotein: Generation, Concentration, and Broad Host Range , 2002, Journal of Virology.

[15]  T. Engber,et al.  Long-acting forms of Sonic hedgehog with improved pharmacokinetic and pharmacodynamic properties are efficacious in a nerve injury model. , 2002, Journal of pharmaceutical sciences.

[16]  G. Kobinger,et al.  Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. , 2001, Human molecular genetics.

[17]  T. Kafri.  Lentivirus vectors: difficulties and hopes before clinical trials. , 2001, Current opinion in molecular therapeutics.

[18]  James M. Wilson,et al.  “Stealth” Adenoviruses Blunt Cell-Mediated and Humoral Immune Responses against the Virus and Allow for Significant Gene Expression upon Readministration in the Lung , 2001, Journal of Virology.

[19]  G. Kobinger,et al.  Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo , 2001, Nature Biotechnology.

[20]  F. Veronese.  Peptide and protein PEGylation: a review of problems and solutions. , 2001, Biomaterials.

[21]  L. Chang,et al.  Kinetic analyses of stability of simple and complex retroviral vectors. , 2001, Virology.

[22]  P. Sheridan,et al.  VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  J. Wilson,et al.  Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions. , 2000, Human gene therapy.

[24]  B. Davidson,et al.  Feline immunodeficiency virus vectors persistently transduce nondividing airway epithelia and correct the cystic fibrosis defect. , 1999, The Journal of clinical investigation.

[25]  F. Gage,et al.  Rescue from Photoreceptor Degeneration in therd Mouse by Human Immunodeficiency Virus Vector-Mediated Gene Transfer , 1999, Journal of Virology.

[26]  T. Dubensky,et al.  The Resistance of Retroviral Vectors Produced from Human Cells to Serum Inactivation In Vivo and In Vitro Is Primate Species Dependent , 1999, Journal of Virology.

[27]  Alan E. Smith,et al.  PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. , 1999, Human gene therapy.

[28]  M. Ogris,et al.  PEGylated DNA/transferrin–PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery , 1999, Gene Therapy.

[29]  D. Trono,et al.  A Third-Generation Lentivirus Vector with a Conditional Packaging System , 1998, Journal of Virology.

[30]  J. Bennett,et al.  Real-time, noninvasive in vivo assessment of adeno-associated virus-mediated retinal transduction. , 1997, Investigative ophthalmology & visual science.

[31]  D. Peterson,et al.  Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors , 1997, Nature Genetics.

[32]  J. Bennett,et al.  Cell-mediated immune response and stability of intraocular transgene expression after adenovirus-mediated delivery. , 1997, Investigative ophthalmology & visual science.

[33]  F. Gage,et al.  Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[34]  R. Rother,et al.  The α-Galactosyl Epitope: A Sugar Coating That Makes Viruses and Cells Unpalatable , 1996, Cell.

[35]  F. Gage,et al.  In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector , 1996, Science.

[36]  I. Chen,et al.  High-efficiency gene transfer into CD34+ cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G , 1996, Journal of virology.

[37]  I. Plavec,et al.  A novel human amphotropic packaging cell line: high titer, complement resistance, and improved safety. , 1996, Virology.

[38]  E. Setter,et al.  A novel mechanism of retrovirus inactivation in human serum mediated by anti-alpha-galactosyl natural antibody , 1995, The Journal of experimental medicine.

[39]  T. Kararli.  Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals , 1995, Biopharmaceutics & drug disposition.

[40]  D. Russell,et al.  The effects of human serum and cerebrospinal fluid on retroviral vectors and packaging cell lines. , 1995, Human gene therapy.

[41]  M. Woodle,et al.  New amphipatic polymer-lipid conjugates forming long-circulating reticuloendothelial system-evading liposomes. , 1994, Bioconjugate chemistry.

[42]  T Friedmann,et al.  Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[43]  J. Sodroski,et al.  Gene transfer into human lymphocytes by a defective human immunodeficiency virus type 1 vector , 1991, Journal of virology.

[44]  D. Littman,et al.  Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity , 1990, Journal of virology.

[45]  M. Gibaldi,et al.  Noncompartmental Analysis Based on Statistical Moment Theory , 1982 .

[46]  F. Jensen,et al.  Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway , 1976, The Journal of experimental medicine.

[47]  N K Jain,et al.  Pegnology: a review of PEG-ylated systems. , 2002, Die Pharmazie.

[48]  B. Davidson,et al.  Gene transfer to the brain using feline immunodeficiency virus-based lentivirus vectors. , 2002, Methods in enzymology.

[49]  J. M. Harris,et al.  Pegylation: a novel process for modifying pharmacokinetics. , 2001, Clinical pharmacokinetics.

[50]  J. Descotes,et al.  Preclinical safety evaluation of human gene therapy products. , 1999, Toxicological sciences : an official journal of the Society of Toxicology.

[51]  Andrew W. Taylor,et al.  Ocular immunosuppressive microenvironment. , 2007, Chemical immunology and allergy.

[52]  B. Davidson,et al.  Factors that influence stability of recombinant adenoviral preparations for human gene therapy. , 1998, Pharmaceutical development and technology.

[53]  M. Gibaldi,et al.  Apparent Volume of Distribution , 1982 .